Stocks To Buy Now

Blog


DGE’s 4th Investigator-Initiated Trials Conference to Provide Strategies on Building Smooth and Successful Investigator-Initiated Trials

Join us at the 4th Investigator-Initiated Trials Conference on November 11-12th at The Inn at Penn in Philadelphia, PA, where we will dive into strategies for building successful IITs. This event will focus on how to streamline study milestones, master budget forecasting, and enhance sponsor-investigator communication.

Dynamic Global Events has produced an all-new agenda that includes engaging panel discussions, keynotes, and real-world insights from industry leaders at top companies such as Sanofi, Beigene, Merck, Ipsen, Secura Bio, and many more! You will hear strategies on how to ensure global regulatory compliance, develop KPIs, and create the perfect budget for your IITs.

During the event, you can connect directly with experts shaping the future of investigator-led research. There will be designated time for audience interaction and networking to allow you to connect with industry leaders and professionals directly.

Don’t miss this exciting opportunity to drive innovation in healthcare and advance the future of IITs!

To learn more, visit https://ibn.fm/5hKcJ.

From Our Blog

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

March 31, 2026

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing […]

Rotate your device 90° to view site.